Intarcia Therapeutics, Inc.-Product Pipeline Review-2015

Intarcia Therapeutics, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07345CDB
  • |
  • Pages: 24
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Intarcia Therapeutics, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Intarcia Therapeutics, Inc.-Product Pipeline Review-2015', provides an overview of the Intarcia Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Intarcia Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Intarcia Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Intarcia Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Intarcia Therapeutics, Inc.'s pipeline products

Reasons To Buy

Evaluate Intarcia Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Intarcia Therapeutics, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Intarcia Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Intarcia Therapeutics, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Intarcia Therapeutics, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Intarcia Therapeutics, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Intarcia Therapeutics, Inc. Snapshot 4

Intarcia Therapeutics, Inc. Overview 4

Key Information 4

Key Facts 4

Intarcia Therapeutics, Inc.-Research and Development Overview 5

Key Therapeutic Areas 5

Intarcia Therapeutics, Inc.-Pipeline Review 7

Pipeline Products by Stage of Development 7

Pipeline Products-Monotherapy 8

Intarcia Therapeutics, Inc.-Pipeline Products Glance 9

Intarcia Therapeutics, Inc.-Late Stage Pipeline Products 9

Phase III Products/Combination Treatment Modalities 9

Intarcia Therapeutics, Inc.-Clinical Stage Pipeline Products 10

Phase I Products/Combination Treatment Modalities 10

Intarcia Therapeutics, Inc.-Drug Profiles 11

exenatide 11

Product Description 11

Mechanism of Action 11

R&D Progress 11

ITCA-880 13

Product Description 13

Mechanism of Action 13

R&D Progress 13

ITCA-884 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

Intarcia Therapeutics, Inc.-Pipeline Analysis 15

Intarcia Therapeutics, Inc.-Pipeline Products by Target 15

Intarcia Therapeutics, Inc.-Pipeline Products by Route of Administration 16

Intarcia Therapeutics, Inc.-Pipeline Products by Molecule Type 17

Intarcia Therapeutics, Inc.-Pipeline Products by Mechanism of Action 18

Intarcia Therapeutics, Inc.-Recent Pipeline Updates 19

Intarcia Therapeutics, Inc.-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Appendix 23

Methodology 23

Coverage 23

Secondary Research 23

Primary Research 23

Expert Panel Validation 23

Contact Us 23

Disclaimer 24

List of Tables

Intarcia Therapeutics, Inc., Key Information 4

Intarcia Therapeutics, Inc., Key Facts 4

Intarcia Therapeutics, Inc.-Pipeline by Indication, 2015 6

Intarcia Therapeutics, Inc.-Pipeline by Stage of Development, 2015 7

Intarcia Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 8

Intarcia Therapeutics, Inc.-Phase III, 2015 9

Intarcia Therapeutics, Inc.-Phase I, 2015 10

Intarcia Therapeutics, Inc.-Pipeline by Target, 2015 15

Intarcia Therapeutics, Inc.-Pipeline by Route of Administration, 2015 16

Intarcia Therapeutics, Inc.-Pipeline by Molecule Type, 2015 17

Intarcia Therapeutics, Inc.-Pipeline Products by Mechanism of Action, 2015 18

Intarcia Therapeutics, Inc.-Recent Pipeline Updates, 2015 19

Intarcia Therapeutics, Inc., Other Locations 22

List of Figures

Intarcia Therapeutics, Inc.-Pipeline by Top 10 Indication, 2015 6

Intarcia Therapeutics, Inc.-Pipeline by Stage of Development, 2015 7

Intarcia Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 8

Intarcia Therapeutics, Inc.-Pipeline by Top 10 Route of Administration, 2015 16

Intarcia Therapeutics, Inc.-Pipeline by Top 10 Molecule Type, 2015 17

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Intarcia Therapeutics, Inc.; Intarcia Therapeutics, Inc. - Key Therapeutics; Intarcia Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Intarcia Therapeutics, Inc. - News; Intarcia Therapeutics, Inc. - Latest Updates; Intarcia Therapeutics, Inc. - Pipeline; Intarcia Therapeutics, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102135
Site License
USD 3000 INR 204270
Corporate User License
USD 4500 INR 306405



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]